The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
BERIL-1: Biomarker results from targeted sequencing of circulating tumor DNA (ctDNA) and archival tissue in a randomized phase II study of buparlisib (BKM120) or placebo plus paclitaxel in patients with head and neck squamous cell carcinoma (HNSCC).
 
Lisa F. Licitra
Consulting or Advisory Role - Amgen; AstraZeneca; Bayer; Boehringer Ingelheim; Bristol-Myers Squibb; Celgene; Debiopharm Group; Eisai; GlaxoSmithKline; Merck Serono; MSD; Novartis; SOBI; VentiRx
Research Funding - Amgen (Inst); AstraZeneca (Inst); Boehringer Ingelheim (Inst); Eisai (Inst); Exelixis (Inst); Merck Serono (Inst); MSD (Inst); Novartis (Inst); Roche (Inst)
Travel, Accommodations, Expenses - Bayer; Celgene; Debiopharm Group; Merck Serono; MSD; sobi
 
Sandrine J. Faivre
Honoraria - Novartis
Research Funding - Novartis
 
Marie Chol
Employment - Novartis
 
Nadia Solovieff
Employment - Novartis
Stock and Other Ownership Interests - Novartis
Research Funding - Novartis
 
Douglas Robinson
Employment - Novartis
Stock and Other Ownership Interests - Novartis
Patents, Royalties, Other Intellectual Property - Novartis
 
Emmanuelle DiTomaso
Employment - Novartis
Stock and Other Ownership Interests - Novartis
 
Samit Hirawat
Employment - Novartis
Leadership - Novartis
Stock and Other Ownership Interests - Novartis
 
Denis Soulieres
Consulting or Advisory Role - Novartis
Research Funding - Novartis